Drug Profile
Research programme: siRNA therapeutics - OliX Pharmaceuticals
Alternative Names: asiRNA therapeutics - OliX Pharmaceuticals; BMT 101; cp-asiRNA therapeutics - OliX Pharmaceuticals; OLX 10020; OLX 103; OLX 201; OLX 301; OLX 401; OLX 701Latest Information Update: 10 May 2022
Price :
$50
*
At a glance
- Originator BioMolecular Therapeutics
- Developer OliX Pharmaceuticals; University of Virginia School of Medicine
- Class Analgesics; Antifibrotics; Antivirals; Eye disorder therapies; Skin disorder therapies; Small interfering RNA
- Mechanism of Action Connective tissue growth factor inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Brain disorders; Neuropathic pain
- Research COVID 2019 infections
- No development reported Age-related macular degeneration; Atopic dermatitis; Hepatic fibrosis; Idiopathic pulmonary fibrosis
- Discontinued Cancer; Herpes simplex virus infections